AD-FTD Tau-TDP-43 Overlap: Mechanism Comparison

AD-FTD Tau-TDP-43 Overlap: Mechanism Comparison

Overview

Alzheimer's disease (AD) and frontotemporal dementia (FTD) were long viewed as distinct entities — amyloid-beta and tau-driven neurodegeneration versus frontotemporal lobar degeneration (FTLD) characterized by tau or TDP-43 pathology. However, research over the past decade has revealed extensive molecular overlap: TDP-43 proteinopathy is present in approximately 40-57% of AD cases at autopsy, while tau pathology appears in many FTD subtypes, creating a complex landscape of co-pathology that blurs traditional diagnostic boundaries[@neumann2006][@josephsmatter2011].

This page systematically compares the molecular mechanisms of tau and TDP-43 involvement across AD and FTD, examines their distinct and shared spreading mechanisms, delineates clinical phenotypes arising from co-pathology, and explores therapeutic implications of this overlap.

1. Molecular Basis of Tau-TDP-43 Co-Pathology

1.1 TDP-43 in Alzheimer's Disease

TDP-43 pathology in AD was first formally described as "TDP-43 type A" inclusions in 2006 by Arai et al., who observed that a subset of AD cases harbored TDP-43-positive, tau-negative inclusions in the medial temporal lobe[@arai2006]. Subsequent studies by Neumann et al. and others established that TDP-43 inclusions in AD follow a stereotypical pattern: beginning in the hippocampal formation, spreading to the amygdala, and eventually reaching the neocortex in advanced cases[@neumann2006].

AD-FTD Tau-TDP-43 Overlap: Mechanism Comparison

Overview

Alzheimer's disease (AD) and frontotemporal dementia (FTD) were long viewed as distinct entities — amyloid-beta and tau-driven neurodegeneration versus frontotemporal lobar degeneration (FTLD) characterized by tau or TDP-43 pathology. However, research over the past decade has revealed extensive molecular overlap: TDP-43 proteinopathy is present in approximately 40-57% of AD cases at autopsy, while tau pathology appears in many FTD subtypes, creating a complex landscape of co-pathology that blurs traditional diagnostic boundaries[@neumann2006][@josephsmatter2011].

This page systematically compares the molecular mechanisms of tau and TDP-43 involvement across AD and FTD, examines their distinct and shared spreading mechanisms, delineates clinical phenotypes arising from co-pathology, and explores therapeutic implications of this overlap.

1. Molecular Basis of Tau-TDP-43 Co-Pathology

1.1 TDP-43 in Alzheimer's Disease

TDP-43 pathology in AD was first formally described as "TDP-43 type A" inclusions in 2006 by Arai et al., who observed that a subset of AD cases harbored TDP-43-positive, tau-negative inclusions in the medial temporal lobe[@arai2006]. Subsequent studies by Neumann et al. and others established that TDP-43 inclusions in AD follow a stereotypical pattern: beginning in the hippocampal formation, spreading to the amygdala, and eventually reaching the neocortex in advanced cases[@neumann2006].

The prevalence of TDP-43 pathology in AD varies by cohort and detection method:

• Approximately 20-30% of clinically diagnosed AD cases show TDP-43 inclusions at autopsy
• Up to 50-57% show TDP-43 pathology when sensitive antibodies are used
• Limbic-predominant TDP-43 in AD correlates strongly with memory impairment beyond what tau alone would predict[@wilson2013]

• Phosphorylation: TDP-43 in AD shows hyperphosphorylation at serine 409/410, similar to FTLD-TDP
• Truncation: C-terminal fragments of TDP-43 are detected in AD brains
• Mislocalization: TDP-43 shifts from nuclear to cytoplasmic compartments
• Upregulation: Total TDP-43 levels are increased in AD cortex, suggesting transcriptional dysregulation[@jefferson2017]

1.2 Tau Pathology in Frontotemporal Dementia

Tau pathology in FTD is heterogeneous, spanning multiple 3R, 4R, and mixed 3R/4R tauopathies. The FTLD-tau spectrum includes:

• Pick's disease (3R tau): spherical Pick bodies, frontal/temporal atrophy
• Progressive supranuclear palsy (PSP) (4R tau): globose neurofibrillary tangles, brainstem involvement
• Corticobasal degeneration (CBD) (4R tau): astrocytic plaques, asymmetric cortical atrophy
• FTLD-tau with MAPT mutations: familial forms with pathogenic variants in the [MAPT](/genes/mapt) gene

• Is independent of amyloid-beta deposition
• Shows selective vulnerability of frontal and temporal regions
• May involve specific tau splice isoforms (3R vs 4R dominance)
• Can be driven by genetic mutations in MAPT or other tau-related genes[@dickson2012]

1.3 Primary Age-Related Tauopathy (PART)

PART represents a key intersection between AD and FTD. Josephs et al. (2014) described PART as a distinct entity characterized by:

• Braak stage I-IV tau pathology (neurofibrillary tangles)
• Minimal or no amyloid-beta co-pathology
• TDP-43 co-pathology in up to 80% of cases[@josephsmatter2011]

1.4 APOE and Genetic Modifiers

The [APOE](/genes/apoe) gene strongly influences tau-TDP-43 co-pathology patterns in AD:

• APOE epsilon 4 (APOE4): Associated with increased amyloid-beta deposition and more extensive TDP-43 pathology. APOE4 carriers with AD show higher rates of TDP-43 co-pathology than non-carriers[@chen2019]
• APOE epsilon 2 (APOE2): May be protective against amyloid-beta but does not prevent TDP-43 accumulation
• ABCA7: Genetic variants near ABCA7 are associated with increased AD risk and may influence TDP-43 pathology indirectly[@crane2016][@biffi2020]

• TMEM106B: Common variant (rs3173615) influences TDP-43 pathology burden in FTLD-TDP, particularly in C9orf72 expansion carriers
• GRN and C9orf72: Mutations directly cause TDP-43 proteinopathy in familial FTD
• MAPT: H1/H2 haplotypes and specific mutations drive tau pathology

2. AD vs FTD Pathological Signatures

2.1 Tau Pathology Signatures

| Feature | Alzheimer's Disease | Frontotemporal Dementia |
|---------|--------------------|------------------------|
| Primary tau species | 3R+4R mixed | 3R (Pick's), 4R (PSP, CBD), or mixed |
| Neurofibrillary tangle distribution | Braak stages I-VI (limbic → isocortex) | Regional: frontal/temporal cortex; variable brainstem |
| Topographic pattern | Hippocampus → entorhinal → neocortex | Frontal, temporal poles, basal ganglia |
| Amyloid-beta co-pathology | Universal (>95%) | Rare (<5% in pure FTLD-tau) |
| Spreading mechanism | Prion-like templating, exosome-mediated | Prion-like, exosome, trans-synaptic |
| Tau isoform expression | Balanced 3R/4R | Disease-specific imbalance |
| Post-translational modifications | Hyperphosphorylation, truncation, glycation | Hyperphosphorylation, specific conformational changes |

2.2 TDP-43 Pathology Signatures

| Feature | AD-Associated TDP-43 | FTD (FTLD-TDP) |
|---------|----------------------|----------------|
| Frequency in disease | 20-57% of AD cases | ~50% of FTD cases |
| Inclusion morphology | Dense, compact cytoplasmic inclusions; dystrophic neurites | Type A (compact), Type B (lentiform), Type C (neuronal intranuclear) |
| Anatomical distribution | Hippocampus → amygdala → neocortex | Frontal cortex, basal ganglia, motor neurons |
| C9orf72 association | Rare | Common (40% of familial FTD) |
| Dipeptide repeat proteins | Absent | Present in C9orf72 cases |
| Primary vs secondary | Secondary to AD neuropathology | Primary driver of neurodegeneration |
| Relationship to tau | Co-existing, often accelerates cognitive decline | May co-exist, especially in FTD with motor neuron disease |

2.3 LATE-NC: Limbic-Predominant Age-Related TDP-43 Encephalopathy

LATE-NC was formalized as a distinct neuropathological change in 2019, representing:

• TDP-43 proteinopathy confined predominantly to limbic structures
• Amnesia-predominant clinical syndrome
• Often co-exists with AD neuropathology[@tsuji2017][@nordengen2019]

• It primarily affects older individuals (>80 years)
• The neuroanatomical distribution is limbic-predominant
• It is frequently comorbid with AD neuropathology
• It may represent the third most common dementia pathology after amyloid and tau

3. Spreading Mechanisms: Prion-Like Tau vs TDP-43 Granules

3.1 Tau Propagation (Prion-Like)

Tau propagation in both AD and FTD follows prion-like principles[@carraro2024]:

Template-driven misfolding: Pathological tau recruits native tau molecules, converting them into the same conformer. This creates "tau strains" that are disease-specific and maintain their identity during propagation[@kaufman2016][@sanders2014].

Cell-to-cell spread: Multiple mechanisms facilitate intercellular tau transfer:

• Synaptic vesicle release: Tau is released at presynaptic terminals in activity-dependent manner
• Extracellular vesicles / exosomes: Particularly important in PSP and AD
• Direct cell-to-cell contact: Tunneling nanotubes transfer tau between neurons
• Fluid-phase uptake: Extracellular tau can be taken up by bulk endocytosis

• Neuronal activity increases tau release
• Neuroinflammation enhances microglial uptake and spread
• Aging reduces chaperone-mediated clearance, increasing extracellular tau accumulation

3.2 TDP-43 Propagation: Phase Separation and Granule Dynamics

TDP-43 spreading differs mechanistically from tau in several key ways[@polanco2023]:

Phase separation and granule formation: Under cellular stress, TDP-43 undergoes liquid-liquid phase separation (LLPS), forming stress granules and other membrane-less organelles. This is a physiological response to stress, but in disease states:

• Persistent stress granules become pathological
• TDP-43 within granules can undergo further aggregation
• Liquid-to-solid transitions create seeding-competent species

• Gain-of-function: Accumulation of TDP-43 aggregates disrupts normal nuclear and cytoplasmic functions
• Loss-of-function: Sequestration of functional TDP-43 impairs RNA processing
• Stress granule dynamics: TDP-43 pathology propagates through stress granule biology rather than prion templating

3.3 Cross-Seeding Between Tau and TDP-43

Evidence for direct cross-seeding is limited but emerging:

• In vitro: TDP-43 fibrils can co-aggregate with tau under specific conditions, but templating is weak
• In vivo: Co-pathology of tau and TDP-43 is extremely common, but whether one directly seeds the other remains debated
• Hypothesis: Rather than direct cross-seeding, both proteins may be independently driven to aggregate by shared upstream stressors (e.g., oxidative stress, autophagy impairment, nuclear pore dysfunction)

4. Clinical Overlap: When AD Meets FTD Phenotypes

4.1 AD Patients with FTD-Like Features

Patients with AD can present with FTD-like clinical phenotypes due to:

• Frontotemporal variant AD: Aβ pathology predominantly affecting frontal regions, producing executive dysfunction and behavioral changes reminiscent of bvFTD
• Posterior cortical atrophy (PCA): Typically AD pathology with visuospatial deficits, but can overlap with the logopenic variant of primary progressive aphasia (lvPPA)
• TDP-43 co-pathology: The presence of TDP-43 in AD accelerates memory decline but may also introduce non-amnestic features

4.2 FTD Patients with AD-Like Features

Conversely, FTD patients may present with AD-like syndromes:

• AD phenocopy: Some FTLD-tau cases present with progressive memory loss mimicking AD, particularly in older patients
• PART with TDP-43: Older FTD patients with PART pathology often show memory-predominant phenotypes
• Semantic variant PPA (svPPA): Can be mistaken for AD memory loss if language features are not carefully assessed

4.3 Specific Clinical Syndromes at the AD-FTD Interface

Logopenic variant PPA (lvPPA):

• Initially linked to AD pathology (left posterior temporal-parietal atrophy)
• Now recognized to frequently involve TDP-43 pathology
• Represents a clinical syndrome where AD and FTD features intersect
• Speech apraxia and anomia predominate; often progresses to generalized cognitive decline

• Typically FTLD-tau or FTLD-TDP
• Can be mimicked by frontal-variant AD
• Approximately 20-30% of clinically diagnosed bvFTD patients have AD pathology at autopsy

• Predominantly FTLD-tau (Pick's disease) or FTLD-TDP type C
• Loss of word and object knowledge
• AD pathology is uncommon unless amyloid co-pathology is present

4.4 Diagnostic Challenges

5. Therapeutic Implications

5.1 Therapeutic Approaches for Tau-TDP-43 Co-Pathology

The overlap between AD and FTD creates both challenges and opportunities for therapy development[@serra2020]:

Anti-tau therapies (potentially relevant for both AD and FTD-tau):

• Immunotherapies: Aducanumab, lecanemab target amyloid-beta but also reduce tau pathology indirectly; active tau immunotherapies (gosuranemab, semorinemab) have been tested in PSP with limited success
• Small molecule tau aggregation inhibitors: Methylene blue derivatives, BBSwitch, etc.
• Gene therapy: ASO targeting MAPT mRNA (e.g.,IONP-PD) under investigation for PSP and FTD
• Proteolysis targeting chimeras (PROTACs): Tau-targeting degraders in pre-clinical development

• ASOs targeting TDP-43 mRNA: Under investigation in ALS and FTD to reduce TDP-43 expression
• Nuclear import modulators: Enhancing nuclear import of TDP-43 to prevent cytoplasmic aggregation
• Stress granule disruptors: Preventing liquid-to-solid transition of TDP-43 condensates
• Autophagy enhancers: Promoting clearance of TDP-43 aggregates via the autophagy-lysosome pathway

5.2 Shared Upstream Targets

Both tau and TDP-43 aggregation respond to shared upstream stressors, suggesting common therapeutic targets:

| Upstream Target | Mechanism | Therapeutic Approach |
|----------------|-----------|---------------------|
| Autophagy impairment | Reduced clearance of protein aggregates | mTOR inhibitors, trehalose, BET inhibitors |
| Neuroinflammation | Microglial activation promotes spreading | TREM2 agonists, anti-inflammatory approaches |
| Oxidative stress | Accelerates aggregation kinetics | Nrf2 activators, antioxidants |
| Mitochondrial dysfunction | Energy stress promotes stress granules | Mitochondrial biogenesis activators |
| RNA dysregulation | TDP-43 loss of function disrupts splicing | Splicing modulators |
| Nuclear pore dysfunction | Impaired nuclear-cytoplasmic transport | Nuclear transport modulators |

5.3 Clinical Trial Considerations

For trials targeting AD-FTD overlap syndromes:

• Patient stratification: Biomarker-based stratification is essential — patients with TDP-43 co-pathology may respond differently to anti-tau therapies
• Endpoint selection: Cognitive endpoints may be confounded by co-pathology; fluid biomarkers (p-tau217, NfL, neurogranin) may be more specific
• Genetic considerations: APOE4 carriers with AD show higher TDP-43 burden and may need separate dosing/treatment arms
• Combination therapy: Given the dual pathology, combination approaches targeting both tau and TDP-43 may be most effective

6. Comparison Matrix: AD vs FTD Tau-TDP Overlap

| Dimension | Alzheimer's Disease | Frontotemporal Dementia |
|-----------|--------------------|------------------------|
| Primary proteinopathy | Amyloid-beta + tau | Tau (FTLD-tau) or TDP-43 (FTLD-TDP) |
| TDP-43 co-pathology rate | 20-57% | 50% (FTLD-TDP subtype) |
| Tau isoform balance | 3R+4R mixed | 3R, 4R, or mixed (disease-dependent) |
| Spreading mechanism | Prion-like templating | Prion-like (tau) or phase separation (TDP-43) |
| Primary anatomical target | Hippocampus, entorhinal cortex | Frontal, temporal cortex; basal ganglia |
| Amyloid co-pathology | Universal | Rare in pure FTD |
| Genetic drivers | APOE4, TREM2, ABCA7 | MAPT, GRN, C9orf72, VCP, TMEM106B |
| Key clinical phenotypes | Memory, visuospatial, language | Behavioral, language, motor |
| Therapeutic targets | Anti-Aβ, anti-tau, anti-TDP-43 | Anti-tau, anti-TDP-43, gene-specific |
| Biomarkers | CSF Aβ42, p-tau217, tau PET | CSF NfL, genetic testing, tau PET (limited) |

7. Conclusion

The overlap between AD and FTD at the molecular level reveals that these traditionally separated diseases share more than previously appreciated. TDP-43 pathology is present in a substantial minority of AD cases and accelerates cognitive decline, while tau pathology is a feature of many FTD subtypes. The emergence of PART and LATE-NC as distinct entities further emphasizes that the neuropathological landscape of late-life dementia is a continuum rather than discrete categories.

Understanding the mechanistic intersection of tau and TDP-43 across AD and FTD has several practical implications:

The dense cross-linking between tau and TDP-43 biology across AD and FTD makes a compelling case for integrated therapeutic strategies that address both proteinopathies, particularly in the aging population where co-pathology is the norm rather than the exception.

See Also

• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — Disease overview
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) — General TDP-43 mechanism page
• [FTD-TDP Pathology](/mechanisms/ftd-tdp-pathology) — FTD-specific TDP-43 mechanisms
• [Tau Pathology in AD](/mechanisms/tau-pathology-ad) — AD tau mechanisms
• [Tauopathies Comparison Matrix](/mechanisms/tauopathies-comparison-matrix) — Cross-tauopathy comparison
• [AD vs PD Neuroinflammation](/mechanisms/ad-pd-neuroinflammation-comparison-matrix) — Cross-disease neuroinflammation
• [Primary Age-Related Tauopathy](/mechanisms/primary-age-related-tauopathy) — PART mechanisms
• [TDP-43 Phase Separation Pathway](/mechanisms/tdp43-rna-granule-pathway) — TDP-43 granule biology
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum) — Overlap between ALS and FTD